Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATE(S) AGAINST INFECTIOUS RESPIRATORY ILLNESSES, INCLUDING COVID-19 AND RSV, IN HEALTHY INDIVIDUALS

NCT05886777 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05886777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05886777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATE(S) AGAINST INFECTIOUS RESPIRATORY ILLNESSES, INCLUDING COVID-19 AND RSV, IN HEALTHY INDIVIDUALS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 5, 2023
Completion date
January 1, 2024
Enrollment
1,142 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants